Switch theme
Sign up to access all valuation multiples
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
1998
28
Last FY Revenue n/a
LTM EBITDA -$31.1M
$90.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oncolytics Biotech has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$31.1M.
In the most recent fiscal year, Oncolytics Biotech achieved revenue of n/a and an EBITDA of -$34.6M.
Oncolytics Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oncolytics Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$31.1M | XXX | -$34.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$30.7M | XXX | -$35.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$27.3M | XXX | -$31.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Oncolytics Biotech's stock price is $1.
Oncolytics Biotech has current market cap of $101M, and EV of $90.9M.
See Oncolytics Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $90.9M | $101M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Oncolytics Biotech has market cap of $101M and EV of $90.9M.
Oncolytics Biotech's trades at n/a EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate Oncolytics Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncolytics Biotech has a P/E ratio of -3.7x.
See valuation multiples for Oncolytics Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $101M | XXX | $101M | XXX | XXX | XXX |
| EV (current) | $90.9M | XXX | $90.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.9x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | -3.0x | XXX | -2.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.7x | XXX | -3.2x | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOncolytics Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Oncolytics Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncolytics Biotech's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oncolytics Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncolytics Biotech acquired XXX companies to date.
Last acquisition by Oncolytics Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Oncolytics Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oncolytics Biotech founded? | Oncolytics Biotech was founded in 1998. |
| Where is Oncolytics Biotech headquartered? | Oncolytics Biotech is headquartered in United States of America. |
| How many employees does Oncolytics Biotech have? | As of today, Oncolytics Biotech has 28 employees. |
| Who is the CEO of Oncolytics Biotech? | Oncolytics Biotech's CEO is Mr. Wayne Pisano. |
| Is Oncolytics Biotech publicy listed? | Yes, Oncolytics Biotech is a public company listed on NAS. |
| What is the stock symbol of Oncolytics Biotech? | Oncolytics Biotech trades under ONCY ticker. |
| When did Oncolytics Biotech go public? | Oncolytics Biotech went public in 2001. |
| Who are competitors of Oncolytics Biotech? | Similar companies to Oncolytics Biotech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Oncolytics Biotech? | Oncolytics Biotech's current market cap is $101M |
| Is Oncolytics Biotech profitable? | Yes, Oncolytics Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oncolytics Biotech? | Oncolytics Biotech's last 12 months EBITDA is -$31.1M. |
| What is the current EV/EBITDA multiple of Oncolytics Biotech? | Current EBITDA multiple of Oncolytics Biotech is -2.9x. |
| What is the current FCF of Oncolytics Biotech? | Oncolytics Biotech's last 12 months FCF is -$38.9M. |
| What is the current EV/FCF multiple of Oncolytics Biotech? | Current FCF multiple of Oncolytics Biotech is -2.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
